There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, XORTX Therapeutics (CVE:XRTX) stock is up 133% in the last year, providing strong gains for shareholders.

XORTX Therapeutics Inc. Annual stock financials by MarketWatch. View the latest XRTX financial statements, income statements and financial ratios.

Market CapCA$5.05M Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.Market cap ...

XORTX Therapeutics Inc. Annual stock financials by MarketWatch. View the latest XRTX financial statements, income statements and financial ratios.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

XORTX Therapeutics (XRTX) stock rallied on Friday after the biopharmaceutical company announced an agreement to acquire a Renal Anti-Fibrotic Therapeutic Program from ...

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces the ...

Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | ...

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.